Welcome to our dedicated page for UNITED THERAPEUTICS SEC filings (Ticker: UTHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt, through a family trust, exercised 9,500 stock options at $135.42 on July 21, 2026, acquiring 9,500 common shares, then sold 9,500 shares in multiple open-market trades at weighted-average prices between $523.81 and $537.13. These trades were made under a pre-arranged Rule 10b5-1 trading plan adopted November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. Following this option exercise, a family trust holds 303,410 stock options, while Rothblatt also directly owns 40,513 common shares and has additional indirect holdings including 166 shares held by a spouse.
United Therapeutics Chairperson & CEO Martine Rothblatt, through family trusts, exercised 9,500 stock options at $135.42 per share into common stock on July 20, 2026, then sold an equal 9,500 shares in multiple open-market trades. The transactions were effected under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which permits the exercise of up to 1,734,410 options expiring March 15, 2027, or runs until December 31, 2026. After this exercise, a family trust continues to hold 312,910 stock options, while Rothblatt also holds 40,513 common shares directly and 166 shares indirectly via her spouse.
Martine A. Rothblatt, Chairperson & CEO of United Therapeutics, reported an exercise-and-sale sequence involving company stock on July 17, 2026. Family trusts associated with the reporting person exercised 9,500 stock options at $135.42 per share and sold 9,500 common shares across 11 transactions at weighted-average prices ranging from $528.39 to $542.49.
All transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options (expiring March 15, 2027) or December 31, 2026. After the reported trades, family trusts and related indirect holdings reported 324,443 common shares and 322,410 stock options remaining.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.42 per share on July 16, 2026, and on the same date sold 9,500 shares of common stock in multiple trades, including a tranche at a weighted average price of $530.1449 per share. These option exercises and sales were carried out by a family trust under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of the exercise of 1,734,410 stock options expiring March 15, 2027, or December 31, 2026. After these transactions, that family trust held 324,443 shares of United Therapeutics common stock, while Rothblatt also reported 40,513 shares held directly and 331,910 stock options held in a family trust.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt, through family trusts and personal accounts, exercised stock options for 9,500 shares at $135.4200 per share and sold 9,500 shares of common stock in multiple open-market trades at prices between $520.9158 and $534.2733 per share. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which allows for the potential exercise of up to 1,734,410 stock options expiring March 15, 2027, or terminates by December 31, 2026.
United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options for 8,300 shares of common stock at $146.03 per share and sold 8,300 shares in multiple open-market trades at prices between $527.5950 and $536.8526. These trades were executed under a pre-arranged Rule 10b5-1 plan entered into on August 11, 2025, and Mahon continues to hold 80,740 stock options afterward.
UTHR shareholder Paul Mahon filed a notice of proposed sale of 8,300 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services, with a reported aggregate market value of $4,429,637.79 and 42,446,733 common shares outstanding, to be sold on July 16, 2026 on NASDAQ.
The notice also lists five sales during the past three months, each for 8,300 common shares on May 7, May 21, June 4, June 18, and July 2, 2026, with reported gross proceeds ranging from $4,494,840.93 to $4,870,054.05.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt exercised 9,500 stock options at an exercise price of $135.4200 per share and on the same date sold 9,500 common shares in multiple open-market transactions under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. Following these transactions, she holds 40,513 common shares directly and also maintains additional common stock and stock options through family trusts and her spouse.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options for 9,500 shares of common stock at $135.4200 per share and sold 9,500 shares in open-market trades on July 13, 2026, with reported prices including $542.8000 and $533.7022 per share. The exercise and sales were carried out under a pre-arranged 10b5-1 trading plan adopted on November 7, 2025, which continues until the earlier of exercising 1,734,410 stock options expiring March 15, 2027 or December 31, 2026. After these transactions, Rothblatt holds 40,513 shares directly, plus additional indirect common stock and stock option positions in family trusts and a spouse account, including stock options over 349,192 underlying shares at a $135.4200 exercise price expiring March 15, 2027.
UNITED THERAPEUTICS Corp director Richard Giltner reported the vesting of equity compensation and related share issuance. On July 9, 2026, 1,310 restricted stock units vested and converted on a one-for-one basis into 1,310 shares of common stock. Following this RSU vesting and conversion, Giltner holds 21,884 shares of common stock directly. The restricted stock units had no expiration date and were converted at a price of $0.00 per unit, reflecting non-cash equity compensation rather than an open-market purchase or sale.